Extra-skeletal effects of vitamin D

Current Opinion in Endocrinology and Diabetes

Volumn 12, Issue 6, 2005, Pages 464-470

  Bischoff Ferrari, Heike A ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Falls; Muscle; Vitamin D; Vitamin D receptors

Indexed keywords

CALCITRIOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; VITAMIN D;

CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG EFFECT; FALLING; HUMAN; META ANALYSIS; MUSCLE FUNCTION; MUSCLE STRENGTH; RANDOMIZATION; REVIEW; RISK FACTOR; SKELETON; SYSTEMATIC REVIEW;

EID: 29544437679     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000184294.69327.6c     Document Type: Review

References (84)

1. Dawson-Hughes B, Harris SS, Krall EA, Dallai GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337:670-676.
2. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293:2257-2264. Vitamin D in a dose of 700-800 IU reduces hip and any nonvertebral fractures by about one-fourth. Optimal serum 25-OHD levels for fracture prevention are in the range of 90-100 nmol/l.
3. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62:60-65.
4. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79:820-825.
5. Borissova AM, Tankova T, Kirilov G, et al. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 2003; 57:258-261.
6. John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 1999; 8:399-406.
7. Robsahm TE, Tretli S, Dahlback A, Moan J. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 2004; 15:149-158.
8. Lokeshwar BL, Schwartz GG, Selzer MG, et al. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 1999; 8:241-248.
9. Trump DL, Hershberger PA, Bernardi RJ, et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 2004; 89-90:519-526.
10. Kampman E, Slattery ML, Caan B, Potter JD. Calcium, vitamin D, sunshine exposures, dairy products and colon cancer risk (United States). Cancer Causes Control 2000; 11:459-466.
11. Slattery ML, Neuhausen SL, Hoffman M, et al. Dietary calcium, vitamin D, VDR genotypes and colorectal cancer. Int J Cancer 2004; 111:750-756.
12. McAlindon TE, Felson DT, Zhang Y, et al. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med 1996; 125:353-359.
13. Lane NE, Gore LR, Cummings SR, et al. Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Study of Osteoporotic Fractures Research Group. Arthritis Rheum 1999; 42:854-860.
14. Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001; 86:1633-1637.
15. Lind L, Wengle B, Wide L, et al. Hypertension in primary hyperparathyroidism - reduction of blood pressure by long-term treatment with vitamin D (alphacalcidol): a double-blind, placebo-controlled study. Am J Hypertens 1988; 1:397-402.
16. Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229-238.
17. Eyles DW, Smith S, Kinobe R, et al. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005; 29: 21-30.
18. Johnson JA, Grande JP, Roche PC, Kumar R. Immunohistochemical localization of the 1,25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. Am J Physiol 1994; 267:E356-E360.
19. Kallay E, Bises G, Bajna E, et al. Colon-specific regulation of vitamin D hydroxylases - a possible approach for tumor prevention. Carcinogenesis 2005; 19:19.
20. Conde I, Paniagua R, Fraile B, et al. Expression of vitamin D3 receptor and retinoid receptors in human breast cancer: identification of potential heterodimeric receptors. Int J Oncol 2004; 25:1183-1191.
21. Peehl DM, Krishnan AV, Feldman D. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 2003; 133(Suppl 7): 2461S-2469S.
22. Tetlow LC, Woolley DE. Expression of vitamin D receptors and matrix metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro. Osteoarthritis Cartilage 2001; 9:423-431.
23. Li YC, Qiao G, Uskokovic M, et al. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89-90:387-392.
24. MacDonald PN, Baudino TA, Tokumaru H, et al. Vitamin D receptor and nuclear receptor coactivators: crucial interactions in vitamin D-mediated transcription. Steroids 2001; 66:171-176.
25. Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004; 80(Suppl 6):1717S-1720S.
26. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004; 229:1136-1142.
27. Need AG, O'Loughlin PD, Horowitz M, Nordin BE. Relationship between fasting serum glucose, age, body mass index and serum 25 hydroxyvitamin D in postmenopausal women. Clin Endocrinol (Oxf) 2005; 62:738-741.
28. Trump DL, Hershberger PA, Bernardi RJ, et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 2004; 89,90:519-526.
29. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001; 86:888-894.
30. Bises G, Kallay E, Weiland T, et al. 25-hydroxyvitamin D3-1 alpha-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem 2004; 52:985-989.
31. Cross HS, Kallay E, Khorchide M, Lechner D. Regulation of extrarenal synthesis of 1,25-dihydroxyvitamin DS - relevance for colonic cancer prevention and therapy. Mol Aspects Med 2003; 24:459-465.
32. Holt PR, Arber N, Halmos B, et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev 2002; 11:113-119.
33. Kinyamu HK, Gallagher JC, Balhorn KE, et al. Serum vitamin D metabolites and calcium absorption in normal young and elderly free-living women and in women living in nursing homes. Am J Clin Nutr 1997; 65:790-797.
34. Holick MF. Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr 1995; 61 (Suppl):638S-645S.
35. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67:373-378.
36. Dawson-Hughes B, Harris SS, Dallai GE. Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr 1997; 65:67-71.
37. McKenna MJ. Differences in vitamin D status between countries in young adults and the elderly. Am J Med 1992; 93:69-77.
38. Theiler R, Stahelin HB, Tyndall A, et al. Calcidiol, calcitriol and parathyroid hormone serum concentrations in institutionalized and ambulatory elderly in Switzerland. Int J Vitam Nutr Res 1999; 69:96-105.
39. Parikh SJ, Edelman M, Uwaifo GI, et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol metab 2004; 89:1196-1199. Serum 1,25-dihydroxyvitamin D was significantly lower in obese than nonobese participants (105.7 ± 41.1 compared with 124.8 ± 36.7 pmol/liter; P < 0.0001) in both Caucasian and African American adults. The authors show that 1,25-vit D concentrations fall with increasing adiposity.
40. Looker AC, Dawson-Hughes B, Calvo MS, et al. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 2002; 30:771-777.
41. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin d levels and bone mineral density: a population-based study of younger and older adults. Am J Med 2004; 116:634-639. The authors describe that in this national US survey among individuals age 20-49 years, 21% of whites, 48% of Mexican Americans, and 76% of blacks had 25-OHD levels below the midpoint of the reference range (58.3 nmol/L). Among older adults, 32% of whites, 55% of Mexican Americans, and 67% of blacks had levels below the reference midpoint.
42. Nesbyodell S, Scanlon KS, Cogswell ME, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2002; 76:187-192.
43. Holick MF, Shao Q, Liu WW, Chen TC. The vitamin D content of fortified milk and infant formula. N Engl J Med 1992; 326:1178-1181.
44. Melton LJ. Epidemiology of fractures. In: Osteoporosis: Etiology, Diagnosis and Management, pp. 133-154. BL Riggs, LJ Melton (Eds). Raven Press, New York; 1988.
45. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344:333-340.
46. Tinetti ME. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988; 319:1701-1707.
47. Campbell AJ, Reinken J, Allan BC, Martinez GS. Falls in old age: a study of frequency and related clinical factors. Age Ageing 1981; 10:264-270.
48. Tinetti ME, Inouye SK, Gill TM, Doucette JT. Shared risk factors for falls, incontinence, and functional dependence: unifying the approach to geriatric syndromes. JAMA 1995; 273:1348-1353.
49. Boland R. Role of vitamin D in skeletal muscle function. Endocr Rev 1986; 7:434-447.
50. Glerup H, Mikkelsen K, Poulsen L, et al. Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int 2000; 66:419-424.
51. Birge SJ, Haddad JG. 25-Hydroxycholecalciferol stimulation of muscle metabolism. J Clin Invest 1975; 56:1100-1107.
52. Bischoff HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003; 18:343-351.
53. Sorensen OH, Lund B, Saltin B, et al. Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalciferol and calcium. Clin Sci (Lond) 1979; 56:157-161.
54. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88:5766-5772.
55. Sharkey JR, Giuliani C, Haines PS, et al. Summary measure of dietary musculoskeletal nutrient (calcium, vitamin D, magnesium, and phosphorus) intakes is associated with lower-extremity physical performance in home-bound elderly men and women. Am J Clin Nutr 2003; 77:847-856.
56. Simpson RU, Thomas GA, Arnold AJ. Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. J Biol Chem 1985; 260:8882-8891.
57. Bischoff HA, Borchers M, Gudat F, et al. In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 2001; 33:19-24.
58. Endo I, Inoue D, Mitsui T, et al. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 2003; 144:5138-5144.
59. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged >=60 y. Am J Clin Nutr 2004; 80:752-758.
60. Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000; 15:1113-1118.
61. Bischoff-Ferrari HA, Borchers M, Gudat F, et al. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 2004; 19:265-269. First in situ description of the VDR in human muscle tissue. Biopsies were taken from orthopedic patients undergoing hip or back surgery. The number of VDR-positive nuclei in muscle cells decreased significantly with increasing age.
62. Haddad JG, Walgate J, Min C, Hahn TJ. Vitamin D metabolite-binding proteins in human tissue. Biochim Biophys Acta 1976; 444:921-925.
63. Geusens P, Vandevyver C, Vanhoof J, et al. Quadriceps and grip strength are related to vitamin D receptor genotype in elderly nonobese women. J Bone Miner Res 1997; 12:2082-2088.
64. Mowe M, Haug E, Bohmer T. Low serum calcidiol concentration in older adults with reduced muscular function. J Am Geriatr Soc 1999; 47:220-226.
65. Dhesi JK, Bearne LM, Moniz C, et al. Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with vitamin D status. J Bone Miner Res 2002; 17:891-897.
66. Bischoff HA, Stahelin HB, Urscheler N, et al. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 1999; 80:54-58.
67. Bischoff-Ferrari HA, Dawson-Hughes B, Willett CW, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004; 291:1999-2006. This meta-analysis found that vitamin D in any form should reduce a person's risk of falling by more than 20%.
68. Latham NK, Anderson CS, Lee A, et al. A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people: the Frailty Interventions Trial in Elderly Subjects (FITNESS). J Am Geriatr Soc 2003; 51:291-299.
69. Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 2001; 86:3618-3628.
70. Dukas L, Bischoff HA, Lindpaintner LS, et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004; 52: 230-236. This trial found a reduction in the risk of falling with alphacalcidiol only among ambulatory older persons with a calcium intake above 51 2 mg per day.
71. Graafmans WC, Ooms ME, Hofstee HM, et al. Falls in the elderly: a prospective study of risk factors and risk profiles. Am J Epidemiol 1996; 143:1129-1136.
72. Chapuy MC, Pamphile R, Paris E, et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002; 13:257-264.
73. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003; 326:469.
74. Harwood RH, Sahota O, Gaynor K, et al. A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: the Nottingham Neck of Femur (NONOF) Study. Age Ageing 2004; 33:45-51.
75. Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium treatment and environmental adjustment in the prevention of falls and osteoporotic fractures among elderly Danish community residents [abstract]. J Bone Miner Res 2002; 17:1137.
76. Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005; 365:1621-1628. This pragmatic trial found no benefit of 800 IU vitamin D per day in regard to both falls and fractures.
77. Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005; 330:1003. This pragmatic trial found no benefit of 800 IU vitamin D per day in regard to both falls and fractures.
78. Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents severe falls in elderly community-dwelling women: a pragmatic population-based 3-year intervention study. Aging Clin Exp Res 2005; 17:125-132. This pragmatic trial found a significant reduction of serious falls with 400 IU vitamin D per day.
79. Heaney RP. The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 2005; 15:15. This is an excellent review on the dose of vitamin D needed to achieve certain levels of 25-OHD.
80. Pfeifer M, Dobnig H, Begerow B, Suppan K. Effects of vitamin D and calcium supplementation on falls and parameters of muscle function - a prospective, randomized, double-blind multi-center study [abstract]. Journal of Bone and Mineral Research 2004; 19(Suppl 1):1222:S58.
81. Flicker L, MacInnis RJ, Stein MS, et al. Should all older people in residential care receive vitamin D to prevent falls? results of a randomized trial [abstract]. JBMR 2004; 19(Suppl 1):F459:S99.
82. Bischoff-Ferrari HA, Orav EJ, Dawsen-Hughes B. Effect of vitamin D plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial [abstract]. JBMR 2004; 19(Suppl 1):1221:S58.
83. Kiel DP, Broe KE, Chen TC, et al. Higher dose of vitamin D reduces risk of falls in nusrsing home residents [poster]. JBMR 2004; 19(Suppl 1):M494.
84. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16:713-716. Consensus statement on optimal 25-OHD levels.